Defunct Company
Total Trials
18
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,550
NCT02563938
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2015
Completion: Mar 31, 2016
NCT02734849
Study to Evaluate Multiple Doses in Patients With Nasal Polyposis
Phase: Phase 2
Start: Apr 30, 2016
Completion: Jan 31, 2018
NCT02808793
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Start: Jun 30, 2016
Completion: Dec 31, 2018
NCT02859701
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants
Start: Aug 31, 2016
Completion: May 17, 2017
NCT03436797
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
Start: Jan 23, 2018
Completion: Apr 6, 2020
NCT03379311
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
Start: Feb 26, 2018
Completion: Aug 8, 2019
NCT03496571
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Start: Jul 18, 2018
Completion: Jun 24, 2019
NCT03664960
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Start: Nov 14, 2018
Completion: Nov 2, 2021
NCT04324268
A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers
Start: Mar 23, 2020
Completion: Feb 10, 2021
NCT04322604
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Phase: Phase 3
Start: Jun 18, 2020
Completion: Jan 12, 2022
NCT04322708
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
Phase: Phase 2/3
Start: Jul 6, 2020
Completion: Jan 18, 2022
NCT04620811
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Start: Dec 3, 2020
Completion: Jul 7, 2023
NCT04856891
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
Start: May 20, 2021
Completion: Jan 9, 2023
NCT05152563
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Start: Dec 31, 2021
Completion: Jan 20, 2022
NCT05155085
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
Start: Jun 27, 2022
Completion: Apr 17, 2024
NCT05528861
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
Start: Oct 26, 2022
Completion: Apr 18, 2024
NCT06072157
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
Start: Aug 28, 2023
Completion: May 12, 2025
NCT06577116
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001
Start: Aug 28, 2024
Completion: May 21, 2025